Apigenin
Best-in-class: Apigenin
A flavonoid (the calming compound in chamomile) that binds benzodiazepine/GABA sites to ease into sleep, with additional antioxidant and NAD-sparing interest.
Apigenin quick facts
| Suggested dose | ~50 mg before bed (a common protocol). |
| How often | Daily |
| Who it's for | Wind-down and sleep-onset support without melatonin. |
Mild by design — the low receptor affinity means no meaningful tolerance or dependence, and also no dramatic effect. Best as part of an onset stack rather than alone. The aromatase inhibition is worth knowing for anyone managing estradiol deliberately, in either direction, since it is not usually flagged on the label.
How Apigenin actually works
A flavone that binds the benzodiazepine site on GABA-A receptors, though with low affinity — this is the active behind chamomile's reputation rather than a folk explanation. It is also a moderately potent aromatase inhibitor and inhibits CD38, an enzyme that consumes NAD+, which is why it appears in longevity discussions for reasons unrelated to sleep.
Where to get Apigenin
Find Apigenin on iHerb →The evidence for Apigenin
Graded by what exists behind each claim.
✅ Clinically validated
- Chamomile/apigenin has small-trial support for sleep quality and mild anxiety.
- Standalone high-dose human sleep trials are limited (much of the buzz is mechanistic/anecdotal).
📊 Correlative data
- Chamomile's traditional bedtime use aligns with the GABAergic mechanism.
🧪 Theoretical / extrapolated benefits
- Popularized in longevity circles for sleep + NAD/CD38 effects — mechanistically interesting, human data thin.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Apigenin actually does
Apigenin is 5,7,4'-trihydroxyflavone, the flavone that fractionation of chamomile keeps arriving at. Its target is named, and the affinity has been measured: apigenin competitively inhibits the binding of flunitrazepam to the central benzodiazepine site with a Ki of 4 micromolar, with no effect on muscarinic receptors, alpha-1 adrenoceptors, or on muscimol binding to the GABA-A orthosteric site Viola 1995. That is a clean, specific, allosteric-site result, and it is why this molecule is taken seriously at all.
The sign of the effect is disputed, and this is the most important paragraph on the page. One laboratory reported apigenin as anxiolytic in mice in the elevated plus maze at doses comparable to classical benzodiazepines, with no sedation and no muscle relaxation; a tenfold higher dose produced mild sedation — a 26% reduction in ambulatory locomotor activity and a 35% decrement in hole-board parameters Viola 1995. A second laboratory confirmed the binding — apigenin displaced the radioligand Ro 15-1788 from the same site — and then measured what the binding does. In cultured cerebellar granule cells apigenin reduced GABA-activated chloride currents in a dose-dependent way, an effect blocked by co-application of Ro 15-1788; it shortened the latency to picrotoxin-induced convulsions; and in rats it reduced locomotor activity while showing no anxiolytic, myorelaxant or anticonvulsant action Avallone 2000. Reducing GABA current at the benzodiazepine site is the pharmacological opposite of a sleeping pill. Flavonoids at this site behave as positive, negative or null modulators depending on their hydroxylation pattern Hanrahan 2011, so both results can be true of the same molecule in different preparations — but the shelf sells only one of them.
The second mechanism is unrelated to sleep and is why the longevity crowd buys it. Apigenin inhibits CD38, the principal NAD-consuming glycohydrolase, and raises intracellular NAD in cells and in mice Escande 2013. That is a metabolic argument with a measurable currency, and it has nothing to do with the benzodiazepine site.
Cell, rodent, human — and where it stops
Cell: Ki of 4 micromolar at the benzodiazepine site Viola 1995. Hold that number.
Human pharmacokinetics, and this is the arithmetic that decides the product. Eleven healthy adults aged 23 to 41, after an apigenin- and luteolin-free diet, took a single oral bolus of 2 g of blanched parsley per kilogram of body weight, corresponding to 65.8 plus or minus 15.5 micromoles of apigenin. Plasma was sampled at 0, 4, 6, 7, 8, 9, 10, 11 and 28 hours. Peak plasma apigenin was 127 plus or minus 81 nanomolar, reached at 7.2 plus or minus 1.3 hours, and by 28 hours it was below the 2.3 nanomolar detection limit. Twenty-four-hour urinary apigenin averaged 144 nanomoles, which is 0.22 plus or minus 0.16% of the ingested dose Meyer 2006.
Now put the two numbers side by side. 127 nanomolar is 0.127 micromolar. The binding constant at the benzodiazepine site is 4 micromolar Viola 1995. Peak plasma after a deliberately large food bolus is therefore about one thirty-second of the concentration at which half those sites are occupied in a membrane preparation — before subtracting the fraction bound to plasma protein, and before anything has to cross the blood-brain barrier. Roughly 0.2% of the dose survives to be excreted intact Meyer 2006, the rest having been glucuronidated and sulfated. A 50 mg capsule is a smaller apigenin dose than that parsley bolus. Anyone claiming that 50 mg of apigenin occupies benzodiazepine receptors is asking you to accept a thirty-fold gap without arguing for it.
The human trials that exist are chamomile trials, not apigenin trials. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita extract for generalized anxiety disorder Amsterdam 2009; a randomized trial of long-term chamomile treatment for generalized anxiety disorder Mao 2016; and a preliminary trial of a standardized chamomile extract in chronic primary insomnia Zick 2011. A chamomile extract delivers apigenin mostly as apiin, the 7-O-apiosylglucoside, alongside bisabolol, chamazulene and dozens of other constituents. Those results belong to the extract.
The obstacle, said plainly: the anxiety trials enrolled people carrying a DSM diagnosis of generalized anxiety disorder Amsterdam 2009 Mao 2016, and the reader is a healthy adult who wants to fall asleep faster. There is no randomized trial of purified apigenin at 50 mg for sleep in anybody.
Apigenin — which form, and does it matter
Three different molecules are sold under this name. Apigenin aglycone is what a 50 mg capsule contains. Apiin, the apiosylglucoside, is the form in parsley and chamomile, and it has to be hydrolyzed by gut bacteria before the aglycone can be absorbed — which is why the parsley study's peak came 7.2 hours after the meal rather than in the first hour Meyer 2006. Chamomile extract standardized to apigenin content is a third thing again, and it is the only one of the three with human trials attached Amsterdam 2009 Mao 2016 Zick 2011.
The consequence of that delay is a dosing error nobody warns about. If your apigenin comes from a chamomile preparation, peak exposure lands roughly seven hours after you take it Meyer 2006. Taken at 10 p.m. that is 5 a.m. A bedtime dose of a glycoside is not a bedtime dose of the aglycone.
Solubility decides the rest. Apigenin aglycone is poorly water-soluble and heavily conjugated on first pass, which is what the 0.22% urinary recovery is measuring Meyer 2006. Products using a phospholipid complex, a cyclodextrin or a lipid vehicle are attempting to fix exactly this, and none of them has a published human plasma curve. A phytosome milligram is a milligram of complex, not of apigenin.
The dose on the card — about 50 mg before bed — is a protocol, not a trial dose. It came out of the longevity community, where it is taken for CD38 inhibition Escande 2013, and was then reused for sleep. No trial has used it for either purpose.
What would have to be true, and how you would know it was not
1. Sleep onset, on a diary with a real baseline. Fourteen nights of diary before the first capsule, then 28 nights on 50 mg at a fixed time, estimating sleep-onset latency in the morning rather than watching a clock. Score the Insomnia Severity Index at day 0 and day 28 as the formal instrument. Predict no change beyond regression to the mean, because there is no trial at this dose and the plasma arithmetic is thirty-fold short of the binding constant Meyer 2006 Viola 1995.
2. The prediction that cuts against the product, and it follows from the pharmacology rather than from cynicism. Predict that a minority of people who feel anything at 50 mg feel activated rather than sedated. The one electrophysiological study of this molecule at this site found reduced GABA-activated chloride currents and a shortened latency to chemically induced convulsions Avallone 2000. A wired feeling on a sleep supplement is a prediction of the receptor data, not a paradox, and it is the observation that would tell you which of the two published sign conventions applies to you.
3. The metabolic arm has an actual marker. Whole-blood NAD before and after 8 weeks at a fixed dose. Predict no measurable rise, because CD38 inhibition was demonstrated in cells and mice Escande 2013 and the human oral exposure is nanomolar Meyer 2006. A rise would be the most interesting result anyone has produced on this molecule.
What will fool you: the stack. Apigenin almost never travels alone — it arrives with magnesium, glycine, theanine or a longevity protocol, and each of those has a sleep effect of its own. One variable, four weeks, or you have tested the shelf.
What nobody has tested yet
Nobody has measured plasma apigenin after a capsule. Every human pharmacokinetic number in this entry comes from parsley Meyer 2006. Ten people, a 50 mg aglycone capsule and eight blood draws would establish whether a supplement dose reaches even the 127 nanomolar the food dose reached, and it has never been published.
Nobody has settled the sign. Two laboratories, one binding site, opposite functional conclusions, twenty-five years apart and never reconciled Viola 1995 Avallone 2000. A single voltage-clamp experiment on recombinant alpha-1 beta-2 gamma-2 GABA-A receptors across a concentration range, with diazepam and a known negative modulator as controls, would resolve it in a week Hanrahan 2011.
Nobody has run apigenin against chamomile head to head. The extract has the trials Amsterdam 2009 Mao 2016 Zick 2011 and the isolate has the market, and no study has asked whether the isolate carries the extract's effect.
And nobody has shown CD38 inhibition in a living human at any oral dose. The enzymology is solid Escande 2013; the translation step — whole-blood or PBMC NAD before and after a supplement course — is a single trial nobody has run.
Apigenin — its own safety story, not its category's
Tolerability is good and the honest complaint is different. Drowsiness is the reported effect; the chamomile trials found the extract well tolerated over weeks to months Amsterdam 2009 Mao 2016. The specific problem with this product is not that it hurts you.
The seizure-threshold question is this molecule's own, and it deserves stating rather than burying. In the study that measured function rather than binding, apigenin reduced GABA-activated chloride currents and shortened the latency to picrotoxin-induced convulsions in rodents Avallone 2000. That is a negative-modulator profile at a site where negative modulation is proconvulsant. It has never been tested in a human at any dose, and the exposure arithmetic argues it is unlikely to matter Meyer 2006 — but if you have epilepsy or take a drug that lowers seizure threshold, this is a reasoned mechanistic argument for leaving a high-dose aglycone alone.
Ragweed cross-reactivity is a real chamomile risk and it transfers only to the extract. Matricaria is an Asteraceae; people allergic to ragweed, mugwort or chrysanthemum can react to chamomile preparations, and there are case reports of anaphylaxis. Purified apigenin does not carry the allergenic proteins; a chamomile extract does Amsterdam 2009.
Additive sedation and antiplatelet activity. Flavones of this class inhibit several CYP enzymes in vitro, so a theoretical interaction exists with drugs cleared that way and the clinical significance has not been established — which means nobody has looked, not that somebody looked and found nothing. Mild antiplatelet activity matters mainly around surgery.
Who should not take it: anyone with epilepsy or on a seizure-threshold-lowering drug, on the mechanistic argument above Avallone 2000; anyone with Asteraceae allergy taking the chamomile form; anyone combining it with alcohol or a prescribed sedative before driving; and anyone using it in place of cognitive behavioral therapy for insomnia, which is the first-line treatment for chronic insomnia and the thing a supplement with no trial at its own dose is most likely to displace.
Sources read for this page
- Viola H, et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica 1995 · PMID 7617761
- Avallone R, et al. Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochemical Pharmacology 2000 · PMID 10751547
- Meyer H, Bolarinwa A, et al. Bioavailability of apigenin from apiin-rich parsley in humans. Annals of Nutrition and Metabolism 2006 · PMID 16407641
- Hanrahan JR, Chebib M, Johnston GA. Flavonoid modulation of GABA(A) receptors. British Journal of Pharmacology 2011 · PMID 21244373
- Escande C, et al. Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome.. Diabetes 2013 · PMID 23172919
- Amsterdam JD, Li Y, et al. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. Journal of Clinical Psychopharmacology 2009 · PMID 19593179
- Mao JJ, Xie SX, et al. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine 2016 · PMID 27912875
- Zick SM, et al. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC Complementary and Alternative Medicine 2011 · PMID 21939549
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: The wind-down rather than the sleep: whether the hour before bed stops feeling like an argument with your own head. Its binding at the benzodiazepine site is low-affinity and calming, so the honest endpoint is how quickly you settle, not how many hours you log.
- How long before it means anything: A week at the same dose at the same time. There is no human sleep trial at the doses people take it at — the popularity is mechanistic and anecdotal — so you are running the only trial you are going to get, and it deserves consistent conditions.
- What will fool you: The company it keeps. Almost nobody takes it alone: it arrives inside a stack with magnesium, glycine or a longevity protocol, and every one of those has a sleep effect of its own. Take it by itself for the fortnight or you are testing the stack and crediting the flavonoid.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Apigenin — safety & side effects
- Well tolerated; drowsiness is the main effect.
- Inhibits several CYP enzymes in vitro — theoretically raising levels of medications cleared that way. Clinical significance is unestablished.
- Mild antiplatelet activity. Additive sedation with alcohol, benzodiazepines, z-drugs, opioids and antihistamines. The combination impairs driving more than either alone and more than most people expect. Long-term safety has not been characterized — the trials run weeks to months, not years. That is a real limit on what anyone can tell you about daily use for a decade.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Apigenin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Apigenin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease disrupts sleep in both directions |
| Ferritin | Low iron drives restless legs, a common hidden cause |
| Vitamin D (25-Hydroxy) | Associated with sleep quality and commonly low |
| Magnesium, RBC | The form worth measuring if you're dosing magnesium |
The Sleep Quality & Recovery panel covers these in one order — 11 markers, $172.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
Apigenin — frequently asked questions
What is Apigenin?
A flavonoid (the calming compound in chamomile) that binds benzodiazepine/GABA sites to ease into sleep, with additional antioxidant and NAD-sparing interest.
What is the suggested dose of Apigenin?
~50 mg before bed (a common protocol). This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Apigenin dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Apigenin?
Coach Cam sources Apigenin from vetted, top-rated brands on iHerb — use the buy link on this page.
Apigenin inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Apigenin is used for
Apigenin appears under 2 goals in the goal router.
Related Sleep supplements
Where this goes next
Apigenin is the onset arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.